REG - CelLBxHealth PLC - Preliminary Fourth Quarter 2025 Financial Results

CellbxhealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260116:nRSP1444Pa&default-theme=true

RNS Number : 1444P  CelLBxHealth PLC  16 January 2026

CelLBxHealth plc ("the Company")

Preliminary Fourth Quarter 2025 Financial Results

 

Guildford, UK and Plymouth Meeting, US - 16 January 2026 - CelLBxHealth plc
(AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests
and services supporting research, drug development and clinical oncology,
announces an update on 2025 unaudited financial results and further cost
rationalisation as it looks to drive commercial progress in 2026.

Preliminary 2025 financial results

The Company now expects to report fourth quarter and full year 2025 revenues
of approximately £0.4 million and £1.4 million respectively. The full year
biopharma and product revenues were £0.3 million and £1.1 million
respectively.  The Company was expecting to achieve revenues of £1.6million
for the year ended 31 December 2025, however a few sales contracts, with an
aggregate value of approximately £0.2 million, were deferred into the first
quarter of 2026.

Cash at 31 December 2025 was £7.3 million, providing a strong balance sheet
from which to execute on the new strategy.

Cost rationalisation

The Company is reducing costs at all levels and consequently has voluntarily
delisted its ordinary shares from trading on the OTCQX Market due to low
trading volume and the associated administrative requirements. The Company's
last day of trading on the OTCQX Market was 31 December 2025. Beginning 2
January 2026, the Company has transitioned to trading on the Pink Limited
Market.

The Company is also rationalising its operations at Guildford into one
facility. Along with headcount reductions and other restructuring activities,
total cost savings are expected to be approximately £5.9 million on an
annualised basis.

Outlook for 2026

Further to the fundraising announced in late November 2025, the Company is now
pursuing its revised business strategy, focused on the delivery of commercial
milestones from its qualified 2026/27 sales pipeline of approximately £12.6
million (risk weighted pipeline of £4.5 million), which underpins its revenue
growth targets

2026 Reporting Calendar

·      April 2026: Q1 2026 financial results and business update

·      June 2026: preliminary FY2025 financial results

·      June 30, 2026: Annual general shareholders' meeting

·      July 2026: Q2 2026 financial results and business update

·      November 2026: Q3 2026 financial results and business update

 

Financial information and auditor review

The preliminary unaudited financial information for the year ended 31 December
2025 set out above has been prepared from the Company's internal management
accounts. The Company has not yet finalised its results for the year ended 31
December 2025. Accordingly, the final audited results may differ from the
preliminary unaudited financial information presented above, and such
differences may be material.

Peter Collins CEO of CelLBxHealth commented:

'The Company remains on track with the execution of its organisational
restructure and delivery of associated cost-saving measures. With management
focused on refining the Company's business strategy, securing funding and
implementing the restructure during the fourth quarter of 2025, some sales
contracts, with an aggregate value of approximately £0.2 million, were
deferred into the first quarter of 2026.'

 

For further information:

 CelLBxHealth plc                                 +44 (0) 1483 343434

 Peter Collins, Chief Executive Officer          investor@cellbxhealth.com

 Cavendish (NOMAD and Broker)                     +44 (0) 20 7220 0500

 Geoff Nash / Isaac Hooper (Corporate Finance)

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 FTI Consulting                                    +44 (0) 203 727 1000

 Simon Conway, Ciara Martin, Sam Purewal

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014) as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended. Upon the publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

Notes for editors

About CelLBxHealth plc

CelLBxHealth plc is a precision CTC intelligence company specialising in
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology. Its patent-protected Parsortix® platform
harvests CTCs from blood and can be integrated with existing laboratory
instruments for comprehensive downstream analysis - including whole-cell
imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales: Accelerating Parsortix
platform adoption and consumable sales through CROs and clinical lab
partnerships. (2) Laboratory services: Clinical trial support and assay
development (3) Lab Developed Tests (LDTs): Strategic partnerships combined
with a focused in-house development programme.

The product portfolio comprises the Parsortix® platform with associated
consumables and assays. Laboratory services are delivered from CelLBxHealth's
GCLP compliant UK laboratory, providing bespoke clinical-trial support and
assay development.

For more information, visit https://cellbxhealth.com/
(https://cellbxhealth.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTXELLFQFLBBBL



            Copyright 2019 Regulatory News Service, all rights reserved